Summit Therapeutics (SMMT) Reports Q1 Loss of GBP0.09/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. TMUS
9. SPY
10. SBUX

Go back to Summit Therapeutics (SMMT) Reports Q1 Loss of GBP0.09/Share

Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2016 and Operational Progress

June 2, 2016 7:01 AM EDT

OXFORD, United Kingdom, June 02, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM: SUMM) (NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (DMD) and C. difficile infection (CDI), today reports its financial results for the first quarter ended 30 April 2016.    

Mr Glyn Edwards, Chief Executive Officer of Summit commented: Our programmes in DMD and CDI both have the potential to significantly improve the current standards of care and are making good progress towards the patients who could... More

Summit Therapeutics to Report Financial Results for the First Quarter Ended 30 April 2016 on 2 June 2016

May 31, 2016 7:00 AM EDT

OXFORD, United Kingdom, May 31, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM: SUMM) (NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its first quarter financial results for the... More